CN101454673B - Sparc及其使用方法 - Google Patents
Sparc及其使用方法 Download PDFInfo
- Publication number
- CN101454673B CN101454673B CN200780019544.0A CN200780019544A CN101454673B CN 101454673 B CN101454673 B CN 101454673B CN 200780019544 A CN200780019544 A CN 200780019544A CN 101454673 B CN101454673 B CN 101454673B
- Authority
- CN
- China
- Prior art keywords
- sparc
- protein
- rna
- tumour
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78820806P | 2006-03-31 | 2006-03-31 | |
US60/788,208 | 2006-03-31 | ||
PCT/US2007/065486 WO2008060651A2 (fr) | 2006-03-31 | 2007-03-29 | Sparc et procédés d'utilisation de celui-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101454673A CN101454673A (zh) | 2009-06-10 |
CN101454673B true CN101454673B (zh) | 2014-02-12 |
Family
ID=39402301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780019544.0A Expired - Fee Related CN101454673B (zh) | 2006-03-31 | 2007-03-29 | Sparc及其使用方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US8415304B2 (fr) |
EP (1) | EP2010919B1 (fr) |
JP (1) | JP5756596B2 (fr) |
CN (1) | CN101454673B (fr) |
AU (2) | AU2006249235B2 (fr) |
BR (1) | BRPI0710111A2 (fr) |
CA (1) | CA2648118C (fr) |
ES (1) | ES2687076T3 (fr) |
WO (1) | WO2008060651A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
NZ623264A (en) | 2008-12-05 | 2015-09-25 | Abraxis Bioscience Llc | Sparc binding scfvs |
CA2960887C (fr) | 2009-05-28 | 2018-09-04 | Abraxis Bioscience, Llc | Utilisation de 2 anticorps anti-sparc en vue de prevoir la reaction a une chimiotherapie |
JP2013505268A (ja) * | 2009-09-18 | 2013-02-14 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | 癌の治療におけるsparc微小環境シグネチャの使用 |
EP2517003B1 (fr) * | 2009-12-22 | 2017-07-19 | Expression Pathology, Inc. | Dosage srm/mrm de la protéine sécrétée acide et riche en cystéine (sparc) |
KR20130010477A (ko) * | 2010-03-11 | 2013-01-28 | 아브락시스 바이오사이언스, 엘엘씨 | Sparc 혈관형성 영역과 사용방법 |
KR20130028728A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
WO2011123393A1 (fr) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques |
RU2621640C2 (ru) * | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
EP2575863A4 (fr) * | 2010-06-03 | 2014-04-09 | Abraxis Bioscience Llc | Utilisation de la signature du microenvironnement des sparc dans le traitement du cancer |
KR20130108104A (ko) * | 2010-06-03 | 2013-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 말초혈 sparc 결합 항체와 이들의 용도 |
RU2577278C2 (ru) * | 2010-06-07 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
WO2012051220A1 (fr) * | 2010-10-11 | 2012-04-19 | Wichita State University | Système de délivrance de médicaments de nanoparticules magnétiques composites |
SG10201606406PA (en) * | 2011-04-28 | 2016-09-29 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
CA3152081A1 (en) | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
US20170000899A1 (en) * | 2013-11-26 | 2017-01-05 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
GB201721308D0 (en) * | 2017-12-19 | 2018-01-31 | Nordic Bioscience As | SPARC assay |
US20190356621A1 (en) * | 2018-05-17 | 2019-11-21 | Koninklijke Philips N.V. | Adapting silence periods for digital messaging |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
CA2155186A1 (fr) | 1993-02-01 | 1994-08-18 | Kevin M. Ulmer | Methodes et appareil pour le sequencage de l'adn |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
KR960701988A (ko) | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents) |
US5945515A (en) | 1995-07-31 | 1999-08-31 | Chomczynski; Piotr | Product and process for isolating DNA, RNA and proteins |
KR19990063632A (ko) | 1995-09-21 | 1999-07-26 | 디 헤이쓰, 산드라 우드 | 약물 운송용 트란스사이토시스 매개체 및 상승제 |
EP0950097A2 (fr) | 1996-12-27 | 1999-10-20 | Instituto de Investigaciones Bioquimicas Fundacion Campomar | Compositions et methodes destines au traitement de tumeurs |
CA2278678A1 (fr) | 1997-01-31 | 1998-08-06 | Research Corporation Technologies, Inc. | Immunotherapie anticancer a base de cellules semi-allogeniques |
DE19740571C1 (de) | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
EP1100494A1 (fr) | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Composition pharmaceutiquement acceptable comprenant une solution aqueuse de paclitaxel et d'albumine |
US6316193B1 (en) | 1998-10-06 | 2001-11-13 | Origene Technologies, Inc. | Rapid-screen cDNA library panels |
US20020015950A1 (en) | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
US20040018188A9 (en) * | 1999-01-20 | 2004-01-29 | Incyte Genomics, Inc. | Sparc-related proteins |
US6387664B1 (en) | 1999-02-26 | 2002-05-14 | Secretary Of Agency Of Industrial Science And Technology | Sparc fusion protein and method for producing the same |
JP2003500422A (ja) | 1999-05-28 | 2003-01-07 | ユニバーシティー オブ ヴァージニア パテント ファウンデーション | 石灰化した腫瘍および組織を治療するためのオステオネクチンに基づく毒性遺伝子治療 |
WO2001020989A1 (fr) | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Procedes et compositions therapeutiques utilisant des virus de la famille paramyxoviridae de recombinaison |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
JP2004500042A (ja) | 1999-10-04 | 2004-01-08 | ヴァイオン ファーマシューティカルズ、インコーポレーテッド | エフェクター分子の腫瘍標的送達のための組成物および方法 |
EP1285090A1 (fr) | 2000-04-25 | 2003-02-26 | DNA Sciences, Inc. | Detection de variations de sequence nucleotidique via l'activite de correction d'epreuve de polymerases |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
WO2002002771A2 (fr) | 2000-07-05 | 2002-01-10 | Eli Lilly And Company | Nouveau gene hsparc-11 et procedes de fabrication et d'utilisation de ce dernier |
US7572763B2 (en) | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
US20050272052A1 (en) | 2002-04-09 | 2005-12-08 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
AU2003281325A1 (en) | 2002-07-02 | 2004-01-23 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
EP1594433B8 (fr) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Sensibilisant d'une therapie de cancer |
JP2007525167A (ja) * | 2003-04-01 | 2007-09-06 | ジェンザイム・コーポレーション | 乳房内皮細胞発現パターン |
JP2007507222A (ja) * | 2003-05-28 | 2007-03-29 | ゲノミック ヘルス, インコーポレイテッド | 化学療法に対する応答を予測するための遺伝子発現マーカー |
FR2857675B1 (fr) * | 2003-07-18 | 2006-01-13 | Staubli Sa Ets | Cadre lisses et metier a tisser pourvu d'au moins un tel cadre |
CN1922332B (zh) * | 2003-12-31 | 2013-06-12 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
JP4689666B2 (ja) * | 2004-05-14 | 2011-05-25 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | アルブミン結合蛋白質を標的として用いる治療法 |
AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
-
2006
- 2006-12-04 AU AU2006249235A patent/AU2006249235B2/en not_active Ceased
-
2007
- 2007-03-29 AU AU2007319763A patent/AU2007319763B2/en not_active Ceased
- 2007-03-29 EP EP07868202.8A patent/EP2010919B1/fr active Active
- 2007-03-29 BR BRPI0710111-2A patent/BRPI0710111A2/pt not_active Application Discontinuation
- 2007-03-29 US US12/295,068 patent/US8415304B2/en active Active
- 2007-03-29 CN CN200780019544.0A patent/CN101454673B/zh not_active Expired - Fee Related
- 2007-03-29 WO PCT/US2007/065486 patent/WO2008060651A2/fr active Application Filing
- 2007-03-29 CA CA2648118A patent/CA2648118C/fr active Active
- 2007-03-29 JP JP2009503271A patent/JP5756596B2/ja not_active Expired - Fee Related
- 2007-03-29 ES ES07868202.8T patent/ES2687076T3/es active Active
-
2013
- 2013-03-08 US US13/791,009 patent/US8946169B2/en active Active
-
2015
- 2015-01-30 US US14/610,099 patent/US9671406B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
Non-Patent Citations (3)
Title |
---|
Cytochemistry》.1995,第43卷(第8期),第791-800页. * |
Porter PL,et al.Distribution of SPARC in normal and neoplastic human tissue.《Journal of Histochemistry & Cytochemistry》.1995,第43卷(第8期),第791-800页. |
Porter PL,et al.Distribution of SPARC in normal and neoplastic human tissue.《Journal of Histochemistry & * |
Also Published As
Publication number | Publication date |
---|---|
ES2687076T3 (es) | 2018-10-23 |
US9671406B2 (en) | 2017-06-06 |
EP2010919B1 (fr) | 2018-07-11 |
JP2009536816A (ja) | 2009-10-22 |
WO2008060651A3 (fr) | 2008-08-28 |
CN101454673A (zh) | 2009-06-10 |
AU2006249235B2 (en) | 2010-11-11 |
AU2007319763B2 (en) | 2011-11-24 |
US8946169B2 (en) | 2015-02-03 |
US20130178422A1 (en) | 2013-07-11 |
US8415304B2 (en) | 2013-04-09 |
CA2648118A1 (fr) | 2008-05-22 |
AU2006249235A1 (en) | 2007-01-04 |
JP5756596B2 (ja) | 2015-07-29 |
US20150141343A1 (en) | 2015-05-21 |
WO2008060651A8 (fr) | 2009-08-06 |
BRPI0710111A2 (pt) | 2011-08-02 |
CA2648118C (fr) | 2013-01-08 |
WO2008060651A2 (fr) | 2008-05-22 |
AU2007319763A1 (en) | 2008-05-22 |
EP2010919A2 (fr) | 2009-01-07 |
US20090291139A1 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101454673B (zh) | Sparc及其使用方法 | |
CN1980699B (zh) | 利用白蛋白-结合蛋白作为靶标的治疗方法 | |
Whittle et al. | First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma | |
Chung et al. | Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors | |
US8916204B2 (en) | SPARC and methods of use thereof | |
CN103221062A (zh) | 外周血sparc 结合抗体及其用途 | |
Bam et al. | Efficacy of affibody-based ultrasound molecular imaging of vascular B7-H3 for breast cancer detection | |
CN110208535A (zh) | 基于caix分级的癌症治疗 | |
CN102460168B (zh) | 两种抗sparc抗体用于预测对化学疗法的反应的用途 | |
Rossfeld et al. | Biological evaluation of a fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model | |
Bensch | Molecular imaging on the move | |
CN110337590A (zh) | 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140212 Termination date: 20190329 |
|
CF01 | Termination of patent right due to non-payment of annual fee |